- Previous Close
105.27 - Open
103.18 - Bid 102.03 x 900
- Ask 102.63 x 900
- Day's Range
101.51 - 103.22 - 52 Week Range
94.73 - 148.15 - Volume
5,852,239 - Avg. Volume
4,634,907 - Market Cap (intraday)
466.315B - Beta (5Y Monthly) 0.17
- PE Ratio (TTM)
34.10 - EPS (TTM)
3.01 - Earnings Date Feb 5, 2025
- Forward Dividend & Yield 1.45 (1.37%)
- Ex-Dividend Date Aug 16, 2024
- 1y Target Est
941.31
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
www.novonordisk.com71,880
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NVO
View More
Related Videos: NVO
Performance Overview: NVO
Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVO
View MoreValuation Measures
Market Cap
466.31B
Enterprise Value
463.77B
Trailing P/E
34.92
Forward P/E
26.88
PEG Ratio (5yr expected)
1.57
Price/Sales (ttm)
12.23
Price/Book (mrq)
27.29
Enterprise Value/Revenue
12.05
Enterprise Value/EBITDA
23.93
Financial Highlights
Profitability and Income Statement
Profit Margin
35.01%
Return on Assets (ttm)
21.47%
Return on Equity (ttm)
88.73%
Revenue (ttm)
270.58B
Net Income Avi to Common (ttm)
94.72B
Diluted EPS (ttm)
3.01
Balance Sheet and Cash Flow
Total Cash (mrq)
74.88B
Total Debt/Equity (mrq)
47.27%
Levered Free Cash Flow (ttm)
46.04B
Research Analysis: NVO
View MoreCompany Insights: NVO
NVO does not have Company Insights
Research Reports: NVO
View MoreTrump’s Nomination of RFK Jr. to Lead HHS a Potential Industry Headwind
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
RatingPrice TargetCompany preparing to apply for new GLP-1 approvals
Novo Nordisk is a pharmaceutical company based in Denmark. Its key divisions include Diabetes Care, Obesity Care, and Rare Diseases. Key products include Ozempic, Victoza, and insulin for diabetes; Wegovy and Saxenda for obesity; and treatments for rare blood and endocrine disorders. The company has approximately 71,880 employees.
RatingPrice TargetBiopharma Election Impact: Potential Reduced IRA Headwind but Unpredictable Challenges
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
RatingPrice TargetOctober Resets Economic, Interest Rate Expectations
The Portfolio Selector features the Argus Focus List, a group of 30 "best idea" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research’s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are AbbVie Inc (ABBV); Arista Networks Inc (ANET); Regions Financial Corp. (RF); Norwegian Cruise Line Hldgs Lt (NCLH) and the Focus List deletions are Capital One Financial Corp. (COF); Hewlett Packard Enterprise Co (HPE); Novo Nordisk (NVO); Target Corp (TGT).